Novogen subsidiary files IND
Tuesday, 02 December, 2008
Novogen’s US subsidiary Marshall Edwards has filed an investigational new drug (IND) application with the US FDA for its chemo-sensitising agent triphendiol.
Triphendiol - to be used in conjunction with gemcitabine, a nucleoside analogue marketed by Eli Lilly as Gemzar – was granted orphan drug status in January for treatment of pancreatic cancer.
The IND application is to enable a Phase I study in patients with unresectable or metastatic pancreatic and bile duct cancers.
Marshall Edwards’ lead candidate, phenoxodiol, is in Phase III trials for recurrent ovarian cancer.
Novogen has licensed both triphendiol and phenoxodiol to Marshall Edwards, and is now looking at another compound, the mTOR inhibitor NV-128, to act against cancer stem cells.
The compound induces caspase-independent apoptosis via the AKT-mTOR pathway and is being investigated for its action against rapidly dividing cells in solid tumours.
A collaboration with a team from Yale University has found the compound has a high level of potency against cancer stem cells, the company said.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
